Cargando…

L-tyrosine is a promising cancer vaccine adjuvant

Detalles Bibliográficos
Autores principales:	Khong, Hiep, Sharma, Meenu, Dai, Zhimin, Singh, Manisha, Hailemichael, Yared, Overwijk, Willem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652446/ http://dx.doi.org/10.1186/2051-1426-3-S2-P440

Ejemplares similares

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy
por: Hailemichael, Yared, et al.
Publicado: (2014)

Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade
por: Singh, Manisha, et al.
Publicado: (2015)

Induction of systemic anti-melanoma immunity through intratumoral TLR-7/8 activation
por: Singh, Manisha, et al.
Publicado: (2014)

Adjuvants for peptide-based cancer vaccines
por: Khong, Hiep, et al.
Publicado: (2016)

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
por: Hailemichael, Yared, et al.
Publicado: (2013)

Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
por: Singh, Manisha, et al.
Publicado: (2017)

IL-2 analogues: novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy
por: Sim, Geok Choo, et al.
Publicado: (2013)

Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

Poster 2010: A study assessing the safety and efficacy of subcutaneous immunotherapy with a dust mite vaccine with the adjuvant l-tyrosine in a highly sensitized population in a Latin-American city
por: Villa, Ricardo Cardona, et al.
Publicado: (2014)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

Soluble Interleukin-15 Complexes Are Generated In Vivo by Type I Interferon Dependent and Independent Pathways
por: Anthony, Scott M., et al.
Publicado: (2015)

ARV formulated microbicides big promise; as world waits vaccine
por: Ondari, Ronald Orutwa, et al.
Publicado: (2009)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Evaluation of Latent Membrane Protein 1 as a novel vaccine adjuvant
por: Termini, JM, et al.
Publicado: (2012)

Promise and challenges of peptide-poly: ICLC vaccines for adult and pediatric gliomas
por: Okada, Hideho, et al.
Publicado: (2013)

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
por: Kwa, S, et al.
Publicado: (2012)

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells
por: Donahue, Renee N, et al.
Publicado: (2013)

P16-36. Functional genomic immune profile of SIV DNA vaccines delivered by electroporation and combined with molecular adjuvants
por: Boyer, JD, et al.
Publicado: (2009)

Simian immunodeficiency virus-Vpx as an adjuvant for integrase defective lentiviral vector-based vaccines
por: Blasi, M, et al.
Publicado: (2012)

The role of transcription factor Runx2 in tumor infiltrating T cells
por: Mbofung, Rina, et al.
Publicado: (2013)

CYPA, a novel and potential genetic adjuvant enhanced HIV-1 DNA vaccine immunoreactivity
por: Hou, J, et al.
Publicado: (2012)

Adjuvant-dependent cytokine profiles in the context of a DNA prime-protein boost HIV-1 vaccine
por: Buglione-Corbett, R, et al.
Publicado: (2012)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

P11-18. Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV
por: Gunderson, S, et al.
Publicado: (2009)

P02-06. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine
por: Liu, J, et al.
Publicado: (2009)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma
por: Sabado, Rachel L, et al.
Publicado: (2013)

Role of the Brk tyrosine kinase in breast cancer progression
por: Harvey, AJ, et al.
Publicado: (2006)

Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015)

Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 gag
por: Qiu, Jian-Tai, et al.
Publicado: (2006)

Preliminary results for the phase 1 trial of a folate receptor alpha adjuvant cancer vaccine in ovarian and endometrial cancer patients
por: Berry, John S, et al.
Publicado: (2013)

Self-adjuvanted RNActive(® )vaccine induces local immune responses at the injection site leading to potent adaptive immunity in mice and humans
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

Cysteine-Rich Protective Antigen (CyRPA) as promising blood-stage candidate protein for inclusion in a malaria subunit vaccine
por: Favuzza, Paola, et al.
Publicado: (2012)

Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response
por: Antonios, Joseph, et al.
Publicado: (2015)

Sustained release of actives with Montanide™ ISA 51 VG and Montanide™ ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines
por: Ascarateil, Stephane, et al.
Publicado: (2015)

Luminal lactate and tyrosine release during intestinal ischemia in rabbits
por: Lobo, S, et al.
Publicado: (2005)

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
por: Hailemichael, Yared, et al.
Publicado: (2013)

Reductions in tyrosine levels are associated with thyroid hormone and catecholamine disturbances in sepsis
por: Khaliq, W, et al.
Publicado: (2015)

Human circulating basophils lack the features of professional antigen presenting cells
por: Sharma, Meenu, et al.
Publicado: (2012)

Completion of 5-year adjuvant endocrine therapy in the community
por: Makubate, B, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9jbahrcqlt2aina7vn41j0nlqn